

## TrailBio® A9 Dopaminergic Neurons

TrailBio® A9 Dopaminergic Neurons are a highly specialized subtype of midbrain neurons, crucial for motor control and implicated in the pathology of Parkinson's disease. Developed using our proprietary HD-DoE® platform, these neurons are differentiated from human induced pluripotent stem cells (iPSCs) and validated for key dopaminergic and A9-specific markers including TH, MAP2, SOX6, CALB1, NR4A2 and KCNJ6. These cryopreserved cells offer a consistent, ready-to-use in vitro model system for studying A9 dopaminergic function, degeneration, and neuro protective strategies. These cells enable scientists to study disease progression, screen therapeutic compounds, and explore regenerative medicine.



# A9 Specific Phenotype

Express A9 markers TH and SOX6 while lacking CALB1, confirmed by qRT-PCR, ICC, and bulk RNA-seq analysis



#### Complete, Optimized Kit

Cryopreserved cells supplied with media and supplements formulated to support post-thaw recovery and maturation




## Functional Performance


Efficient dopamine synthesis and release for disease modeling and drug screening



#### Disease Relevance

Critical in the study of Parkinson's disease, as the main subtype affected in neurodegeneration





**FIGURE 1.** Trailbio® A9 Dopaminergic Neuron progenitors exhibit high viability upon thaw (day 0) and typical morphology in culture at day 14 post-thaw maturation as shown in brightfield image.






FIGURE 2. Bulk RNA-sequencing confirms the successful stepwise differentiation into dopaminergic neurons. Subsequent comparison of day 14 neurons to the progenitor population demonstrates a marked induction of genes critical for dopaminergic neuron maturation and function.



**FIGURE 3.** Functional analysis of dopamine release from TrailBio® A9 and competitor iPSC-derived dopaminergic neurons. Following stimulation with 50 mM KCl, dopamine secretion was quantified by ELISA. TrailBio® A9 neurons exhibited significantly higher levels of dopamine release.



**FIGURE 4.** Trailbio® A9 Dopaminergic Neurons (day 14 culture) stained for mature neural marker microtubule-associated protein 2 (MAP2), A9 subtype dopaminergic neuron marker tyrosine hydroxylase (TH) and nuclei (DAPI). Images were taken at 10X magnification on the EVOS M7000 Imaging System.

## TrailBio® A9 Dopaminergic Neurons



Product	Cell Density	Kit #
TrailBio® A9 Dopaminergic Neurons Kit includes: Cells, Basal Medium, Plating Supplement and Medium Supplement* *Media kit and individual components are also available	3 X 10 <sup>6</sup> viable cells per vial	KEC05010301

Production		
Donor Information	Human Male	
Source Cell	iPSCs from CD34+ Cord Blood	
Karyotype by G-Banding	Normal	

Handling	
Shipping	Dry Ice
Storage	Liquid Nitrogen
Usage	Research Use Only

### Trailhead® Cells

- **Built from Scratch:** TrailBio® cells are produced by directed differentiation and are built to exhibit the properties of naturally occurring cells
- **HD-DoE® Platform:** Trailhead's proprietary HD-DoE® (High-Dimensional Design-of-Experiments) technology creates an efficient protocol for A9 dopaminergic neurons from iPSCs
- Quality: Cell quality is defined and verified at multiple stages during manufacturing using flow cytometry, gene expression by qRT-PCR, bulk RNA-seq data and functionality of cells is determined by key cellular markers using immunocytochemistry (ICC) data
- Data, Not Hypothesis, Driven: Our methods are based on empirical data obtained using HD-DoE®
- Quality by Design: Product development adheres to a Quality-by-Design standards at all stages
- Cellular Identity: Cell fate is confirmed by molecular and functional attributes

### **Applications**

TrailBio<sup>®</sup> cells are well suited for use in 2D and 3D applications, drug discovery, disease-modeling, drug toxicity, 3D tissue printing, organoid formation, tissue on-a-chip manufacturing and functional assay development.



Contact us: info@trailbio.com

